Endovia Health Sciences (EDVA) Free Cash Flow Growth (3y) (2015 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Free Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | -4.45% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 8.92% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | 23.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.31% |
| Mar 31, 2026 | 39.07% |
| Dec 31, 2025 | 32.85% |
| Sep 30, 2025 | 13.09% |
| Jun 30, 2025 | 39.03% |
| Mar 31, 2025 | 44.30% |
| Dec 31, 2024 | 33.17% |
| Sep 30, 2024 | 12.43% |
| Jun 30, 2024 | 15.66% |
| Mar 31, 2024 | 28.78% |
| Dec 31, 2023 | 53.78% |
| Sep 30, 2023 | 7.50% |
| Jun 30, 2023 | -39.58% |
| Mar 31, 2023 | -64.32% |
| Dec 31, 2022 | -63.33% |
| Sep 30, 2022 | -93.95% |
| Jun 30, 2022 | -53.06% |
| Mar 31, 2022 | -86.07% |
| Dec 31, 2021 | -421.41% |
| Sep 30, 2021 | -641.90% |